Parotid Gland Metastasis from Breast Origin

Bohli M*, Tebra S, Jaffel H and Bouaouina N

Radiotherapy Unit, Farhat Hached Hospital, Sousse Tunisia, Tunisia

Abstract

Introduction: Metastatic involvement of parotid gland from breast carcinoma is rare. According to a literature review, only 24 cases have been reported.

Case report: A 48-year-old woman with a history of left breast cancer complained of swelling in the right parotid gland. Biopsy was performed and made the diagnosis of metastasis from breast carcinoma. The patient was treated by chemotherapy and radiotherapy.

Conclusion: Local control of the disease should not be underestimated and a multimodal treatment combining surgery, radiotherapy and chemotherapy should be given every time it seems possible.

Keywords: Breast cancer; Parotid gland; Metastasis; Radiotherapy

Introduction

Parotid tumors represent 3% of head and neck tumors and 80% of salivary gland tumors [1]. The parotid metastasis from breast carcinoma is extremely rare. To our knowledge 24 cases are published nowadays. There is no therapeutic consensus. The management depends on the stage of the disease and the prognosis is dark. We report a case of parotid gland metastasis of breast cancer with review of the literature.

Case Report

A 48-year-old woman, presented in 2005 a left breast carcinoma classified T2N2aM0 according to TNM classification. She had a mastectomy associated with axillary lymph node dissection. Histological examination revealed an invasive ductal carcinoma (IDC) of 2.5 cm, grade II according to Scarff-Bloom-Richardson score (SBR), hormonal receptors positive; 2 lymph nodes out 7 identified were invaded (2N±7N). She underwent eight cycles of adjuvant chemotherapy with 5-Fluotouracil – Epirubicin – cyclophosphamid (FEC) and paclitaxel followed by locoregional radiotherapy at the dose of 52.2 Gy completed in August 2008. A hormone therapy with tamoxifen was prescribed for five years. In 2013 she presented a pulmonary metastatic relapse treated with five courses of FEC followed by aromasine. One year later, she developed cutaneous metastases treated with tamoxifen. In 2015, she had letrozole for bone progression. In July 2016, physical examination identified a firm right parotid mass measuring 5 cm, not painful and without signs of facial nerve involvement. The biopsy revealed an invasive ductal carcinoma of the breast invading the parotid parenchyma. Chemotherapy combination of capecitabine plus vinorelbine was performed. The evolution was marked by the increase and ulceration of the mass associated with active bleeding (Figure 1) responsible for a decrease in hemoglobin with a level of 5 g/dl. The patient was transfused by two packed red blood cells and trusted us for radiotherapy. Computed tomography revealed a heterogeneous mass of the right parotid measuring 5 cm (Figures 2A and 2B). Haemostatic radiotherapy was given at a dose of 13 Gy in two fractions. Three months after the end of radiotherapy and 12 months after the initial diagnosis, the patient was alive with a stabilization of the parotid mass and disappearance of the bleeding.

Discussion

The parotid metastasis is rare accounting for 9% to 14% of parotid tumors [2]. We select two types of parotid metastases according to their method of spread: lymph node metastases where the neoplastic cells were found in the intra-glandular and peri-glandular lymph nodes of the parotid gland originating from the head and neck tumors, mainly from squamous cell carcinomas and melanomas, and parenchymal metastases by hemotogenous spread [3]. In order of frequency, these tumors were described: bronchial carcinoma, renal cancer, mammary carcinoma, colonic carcinomas, carcinoma of the prostate, carcinoma of the stomach and sarcoma of the uterus [3]. Their frequency was estimated to be 1.8% to 4% of secondary parotid tumors [4]. Dissemination of the breast cancer to the parotid gland is rare. Among 34 patients with parotid metastasis, two of them had a breast origin [5].

Review of literature reveals only 24 cases of parotid metastases from breast cancer (Table 1) [2,6-21]. The mean age was 59.6 years and ranged between 40 and 76 years. Our case has 48 years old. A case of parotid metastasis has been described for a man [10]. The most clinical...
Figure 2 (A and B): Computed tomography scan image of the parotid mass.

| References            | Age (yrs) | Histology (Breast) | Location (Breast) | Staging | Other metastasis | Symptoms | Size (cm) | Therapy | Outcome    |
|-----------------------|-----------|--------------------|-------------------|---------|------------------|----------|-----------|---------|------------|
| Wiesel et al. [6]     | 62        | ILC                | Left              | Stade IV | Left Bone        | Swelling | 5         | RT 40 Gy, HT (tam) | Alive, 8 months |
|                       | 61        | IDC                | Left              | T2N0M0   | Left Bone        | Swelling | 1.5       | Partial parotidectomy + RT4000 rads+ CT (cyclophosphamide, MTX, 5FU) | Alive, 1 year |
|                       | 74        | --                 | Left              | T2N1M0   | Left --          | --        | Mass+FNP | --       | RT30 Gy, CT (Cyclophosphamide, MTX, 5FU) | Alive, 6 years |
| Bisset et al. [7]     | 41        | IDC                | Right             | T0N0M0   | Left None        | FNP, Mass | --        | Radical parotidectomy + RT 50 Gy | Alive, 24 M |
|                       | 65        | --                 | Right             | T2N1M0   | Left None        | Mass      | 5         | RT 50 Gy, 25 fractions | DWD, 22 M |
| Calvo et al. [8]      | 57        | IDC                | Right             | --       | Left --          | Pain      | --        | Parotidectomy | -- |
|                       | 57        | --                 | Right             | --       | Right None       | Mass      | --        | IDEM | -- |
|                       | 66        | --                 | Right             | --       | Left None        | Mass      | --        | Superficial Parotidectomy+ RT-HT | DWD, 3 M |
|                       | 52        | --                 | Right             | --       | Right None       | Mass      | --        | IDEM | DWD, 15 M |
|                       | 57        | --                 | Right             | --       | Right None       | Mass      | --        | IDEM | Alive, 15 M |
| Joyce et al. [10]     | 71        | IDC                | Right             | T2N0M0   | Right None       | Mass+FNP | --        | Radical parotidectomy | -- |
| Szymansky et al. [11] | 66        | IDC                | Right             | --       | Left             | FNP       | --        | Parotidectomy | -- |
|                       | 58        | IDC                | Right             | --       | Right            | Mass      | --        | Parotidectomy, RT, CT | -- |
| Zhang et al. [12]     | 40        | phyl               | Left              | --       | Right Lung       | Mass      | 3         | Excision of a parotid and pulmonary node | Alive, 7 M |
| Laforza et al. [13]   | 52        | IDC                | Left              | T1N0M0   | Left None        | Mass      | 2         | Parotidectomy, docetaxel (6 courses), RT, HT (letrozole) | -- |
| Dungore et al. [2]    | 42        | IDC                | Right             | T3N0M1   | Left Parotid     | Mass      | 4         | Total parotidectomy, lymph node dissection, RT, CT | Lost to follow-up |
| Ramesh et al. [14]    | 63        | ADK                | Right             | M1       | Right Parotid    | Mass      | 3         | HT (anastrozole) | Alive, 3 M |
| Ando et al. [15]      | 67        | IDC                | Left              | T1N3M1   | node Left None   | Mass      | --        | Partial parotidectomy, cepacubine, trastuzumab | Alive, 4 M |
| Cihan et al. [16]     | 70        | IDC                | Left              | pT2N3M0  | Left Thyroid, Bone, Liver | Mass | 2 | Superficial parotidectomy, cervical RT 50 Gy, Paclitaxel 80mg/m2(8 courses) | Lost to follow-up |
| Sellinger et al. [17] | 74        | ILC                | Left              | pT2N1M0  | Right Bone       | FNP       | --        | Parotidectomy | -- |
| Aliath et al. [18]    | 43        | IDC                | Right             | T2N2M1   | bone, liver      | Mass      | 3         | Parotidectomy | DWD, 8 M |
| Duncan et al. [19]    | 76        | IDC                | Right             | --       | Right None       | Mass      | 2         | Letrozole | -- |
| Ackan et al. [20]     | 61        | IDC                | Right             | --       | Right Adrenal    | --        | --        | Parotidectomy + adrenalectomy | Alive, 12 M |
| Kmeid et al. [21]     | 65        | IDC                | Right             | --       | Right None       | Mass      | 2         | Total parotidectomy | -- |
| Current case          | 48        | IDC                | Right             | T2N2M0   | Right Lung, Bone, Skin | Mass | 5 | CT (xeloda), RT 13 Gy en 2 fractions | Alive, 12 M |

Table 1: Table summarizing the 24 cases in the literature and the patients in this report.

Presentation was a palpable mass in the parotid region observed in 75% of cases (18 patients), the mean size was three cm. Peripheral facial paralysis was present in 21% of cases (5 patients). The parotid involvement was homolateral in 58.5% of cases (14 patients) and contralateral in 41.5% of them (10 patients). It was synchronous with a mammary carcinoma in 3 cases [2-20]. A fine needle aspiration cytology (FNAC) is now widely used for parotid tumors with an accuracy of 79 to 97% [22,23]. But it needs a trained and experienced cytologist.
The FNAC permitted to apply the positive diagnosis in 41% of the cases that were published in the literature (10 patients). The biopsy was performed in 21% of cases. Our patient had a biopsy. The FNAC is not current practice in our country yet. Metastatic disease to the parotid gland presents a diagnostic problem [18]. The morphological and immunocytochemical characteristics between a primary salivary duct carcinoma and a metastatic ductal breast carcinoma are similar [18].

The association of negative estrogen receptor and intensive staining for carcinoembryonic antigens (ACE) orientate towards salivary duct carcinoma [2,24]. Some authors believe that the presence of a clinical history of a breast carcinoma asserts the diagnosis of parotid metastases [2]. In our case, the diagnosis was made on the clinical presentation and morphological features. The optimum treatment of a patient with a parotid metastasis from breast origin is not well established given the rarity of the case. It depends on the patient’s condition and the stage of the disease (Table 1).

The surgery represents the treatment of choice when feasible. An appropriate parotidectomy with negative margins and with preservation of the facial nerve when possible is preferred [21]. Most authors suggest a superficial parotidectomy when disease is clinically limited to the superficial lobe [4,25]. It was successful in providing control local in most cases [21]. A total or radical parotidectomy is reserved when the deep lobe or the facial nerve are involved [4,21]. Lymph node dissection is required in the presence of clinical or radiological adenopathy. Propylphatic lymph node dissection is not recommended. Postoperative radiotherapy is recommended to improve local control [4]. Some authors prefer chemotherapy to remove occult and microscopic metastases and indicate radiotherapy in case of larger tumor or close surgical margins [13]. The local control is essential; it helps to avoid morbidities secondary to facial paralysis, ulceration and bleeding of the mass. Our patient was in an advanced stage, she had chemotherapy and palliative radiotherapy. The prognosis of patients presenting with parotid gland metastasis from a distant primary tumor is usually poor, with a 5-year survival rate of 10%. It depends on the type of the tumor and the stage of the disease [2].

Conclusion

A parotid mass in a patient with a history of mammary carcinoma must be considered as a metastasis. It is an extremely rare and aggressive entity with a poor prognosis. A multimodal treatment combining surgery, radiotherapy and chemotherapy should be given every time it seems possible in order to get a better local control and a good quality of life.

References

1. Bonfils P (2007) Tumeurs des glandes salivaires. Tumeurs des glandes salivaires 18: 20-628.
2. Dangore-Khasbage SB, Degwekar SS, Bhowate RR, Bhake A (2009) Metastatic involvement of parotid from carcinoma of the breast: A case report. Oral Maxil Surg 13: 49-53.
3. Seifert G, Hennings K, Caselitz J (1986) Metastatic tumours to the parotid and submandibular glands: Analysis and differential diagnosis of 108 cases. Pathol Resea Prac 181: 684-692.
4. Dequanter D, Lothaire P, Andry G (2005) Secondary malignant tumors of the parotid. Annales d’oto-laryngologie et de chirurgie cervico faciale: Bulletin de la Societe d’oto-laryngologie des hopitaux de Paris. 122: 18-20.
5. Nuyens M, Schuppbach J, Stauffer E, Zbaren P (2006) Metastatic disease to the parotid gland. Otolaryngology-head and neck surgery: Official. J Am Ototaryngol Head Neck Surg 135: 844-848.
6. Wiesel JM, Weshler Z, Sherman Y, Gay I (1982) Parotid gland metastatic carcinoma of breast origin. J Surg Oncol 20: 227-230.
7. Bissett D, Bessell EM, Bradley PJ, Morgan DA, McKenzie CG (1989) Parotid metastases from carcinoma of the breast. Clin Radiol 40: 309-310.
8. Calvo Boizas E, Rodríguez Gutierrez A, Munoz Herrera A, Soría Carreras P (1995) Metastasis of breast carcinoma in parotid. A case report and review of the literature. Acta Otorrinolaringologica espanola 48: 391-3.
9. Kollias J, Gill PG (1997) Superficial parotidectomy for parotid metastases from breast cancer. Breast 6: 108-109.
10. Joyce MR, Awad ZT, Saleem T, Salmo EN, Gormley M, et al. (2000) The parotid gland: An unusual site of metastasis from carcinoma of the breast. J Med Sci 169: 230.
11. Szymanski M, Siwiec H, Olzanski W, Golabek W (2002) Parotid metastases from breast cancer. Wiodomosciki lekarskie 55: 494-497.
12. Zhang JZ, Gu M (2003) Malignant phyllodes tumor of the breast metastatic to the parotid gland diagnosed by fine needle aspiration biopsy. A case report. Acta Cytologica 47: 253-258.
13. Laforga JB, Gasent JM (2009) Mammary invasive duct carcinoma metastatic to parotid gland: Report of a case diagnosed by fine-needle aspiration. Diagn Cytopathol 37: 154-158.
14. Ramesh RS, Manjunath S, Ustad TH, Pais S, Shivakumar K (2010) Breast cancer presenting as parotid tumour - first reported case in literature. Ind J Surg Oncol 1: 76-77.
15. Ando K, Masumoto N, Sakamoto M, Terasaka K, Suzuki T, et al. (2011) Parotid gland metastasis of breast cancer: Case report and review of the literature. Breast Care 6: 471-473.
16. Chan YB, Deniz K, Yilmaz MS (2011) Synchronous parotid and thyroid gland metastases from breast cancer. Breast Care 6: 133-135.
17. Sellinger M, Neubauer K, William M, Hemmerlein B, Friedrich M, et al. (2011) Contralateral metastasis of parotid gland in advanced breast cancer with peripheral facial paralysis. Arch Gynecol Obstet 284: 1557-1560.
18. Alatih P, Kapila K, Hussein S, Amanguno H, Hebbbar HG, et al. (2014) Parotid gland metastasis of breast cancer diagnosed on fine needle aspiration cytology: Case report and review of literature. Cytopathology: Official. J Brit Society Clin Cytol 25: 346-348.
19. Duncan M, Monteiro M, Quante M (2015) Bilateral parotid gland metastases from carcinoma of the breast that presented 25 years after initial treatment. Brit J Oral Maxil Surg 53: 94-96.
20. Akcan F, Cadalli Tatar E, Saylam G, Korkmaz H (2015) Management of breast cancer metastasis to parotid gland. Çagdaş Tip Dergisi 5: 100-130.
21. Kmeid M, Kamar FG, Nasser S, Moukarzel N (2016) Metachronous, single parotid gland metastasis from breast cancer: A case report and review of the literature. Case Rep oncolo Med 2016: 396-5283.
22. Diom ES, Thiam A, Tall A, Ndaiye M, Toure S, et al. (2015) Profile of parotid gland tumours:experience of 93 cases over a period of 16 years. Euro Ann Otorhinolaryngol, Head Neck Dis 132: 9-12.
23. All NS, Nawaz A, Rajput S, Ikram M (2010) Parotidectomy: A review of 112 patients treated at a teaching hospital in Pakistan. Asian Pacific journal of cancer prevention: APJCP 11: 1111-1113.
24. Wick MR, Ockner DM, Mills SE, Ritter JH, Swanson PE (1998) Homologous carcinomas of the breasts, skin, and salivary glands. A histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma, and salivary duct carcinoma. Am J Clin Pathol 109: 75-84.
25. Malata CM, Camilleri IG, Mc Lean NR, Piggott TA, Soames JV (1998) Metastatic tumours of the parotid gland. Brit J Oral Maxil Surg 36: 190-195.